In the world of medical cartel, what doesn’t kill you, mutates, and tries again – part 1.

By Marica Micallef

In the world of medical cartel, what does not kill you, mutates and tries again. So, do vaccines.

After the various Covid-19 vaccines which were pushed on nations in these last two years, from Pfizer to Moderna to Johnson & Johnson to Sputnik to AstraZeneca and others, Big Pharma has not had enough yet.

The medical cartel is adamant to keep on making billions, in its quest to keep healthcare a monopoly. In this piece, divided into two parts, I will be having a look at the vaccines that Big Pharma is coming up with.

Besides having Moderna aiming to make vaccines against fifteen deadly diseases – and the next pandemic[1], which I already examined in another blog, I have also specified how both Moderna, and Pfizer are racing each other in the scientific marathon of “Who will produce the mRNA seasonal flu jabs first.”[2] Since they are racing, one can imagine how much importance they both give to healthcare, which requires due diligence.

For Pfizer, this is not enough to make billions. How about making trillions? In November 2021, the company announced its two-in-one Covid and HIV Drug pill, saying that such a pill cuts the risk of hospitalizations or death by 89%. This is the second “antiviral pill behind Merck’s to demonstrate strong effectiveness for treating Covid at the first sign of illness.”[3]

This is the famous Paxlovid which “was granted an emergency use authorization (EUA) by the Food and Drug Administration (FDA) in December for anyone ages 12 and older who weighs at least 88 pounds and is at high risk for severe disease.” These pills can be taken at home when one tests positive for the coronavirus, lowering the risk of hospital admittance.[4]

And this Paxlovid is already being sold in Australia after it has been made available “on the Pharmaceutical Benefits Scheme from May 1” as announced by Health Minister Greg Hunt.[5]

Then we have a pill from Merck, called molnupiravir (Lagevrio), which had also been granted an EUA by the FDA. However, “some studies suggest that molnupiravir has only a 30% reduction in the risk for hospitalization and death from COVID-19.”[6]

Then we have the AstraZeneca Covid prophylaxis drug, for which it sought emergency use authorization in the U.S. from the same FDA.[7]

Moderna has its hands full, being busy expanding its business. Last June, the British government announced that the said company will be opening a vaccine research and manufacturing centre in UK. “NHS patients will have access to the next generation of vaccines and treatments following an agreement [actually it is a monetary relationship] between the government and Moderna to build a state-of-the-art manufacturing and research and development centre in the UK where cutting-edge mRNA vaccines for a wide range of respiratory diseases, including Covid-19 vaccines that can protect against multiple variants.”[8] Aren’t these vaccines already on the market with the latest Omicron-variant vaccine, whose trials have raised hopes of once-a-year booster?[9] The speed of science is really fast.

Having a manufacturing centre in the UK is not enough. Thanks to a 10-year agreement and manufacturing partnership [again, another monetary relationship] between the state and federal governments, Moderna will establish its headquarters and a regional centre in Victoria, where it will produce up to 100 million mRNA vaccine doses per year. Its vaccine production facility will be located at Monash University in Melbourne.[10]